anonymous
Guest
anonymous
Guest
Are there any reps out there who have had Erbitux and Cyramza in their portfolio? I'm just curious as to what the current market conditions and attitudes are towards them. Seems they are in pretty crowded fields with similar results but lower costs? I know that Cyramza was recently approved for a new indication that seems to have a very positive response from the community.